Evidence map›Paper›PMID 40253396›Full record

ArticleScientific data2025

Large-scale human myeloma cell line small molecule compound screen dataset.

V Keith Hughitt, John K Simmons, Sayeh Gorjifard, Aleksandra Michalowski, Kelli Wilson, Xiaohu Zhang, Paul Shinn, Carleen Klumpp-Thomas, Crystal McKnight, Zina Itkin and 5 more

Abstract readDataset
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific data, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

V Keith HughittLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
John K SimmonsLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Sayeh GorjifardLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Aleksandra MichalowskiLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Kelli WilsonChemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Bethesda, MD, USA.
Xiaohu ZhangChemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Bethesda, MD, USA.
Paul ShinnChemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Bethesda, MD, USA.
Carleen Klumpp-ThomasChemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Bethesda, MD, USA.
Crystal McKnightChemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Bethesda, MD, USA.
Zina ItkinChemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Bethesda, MD, USA.
Lu ChenChemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Bethesda, MD, USA.
Sam MichaelChemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Bethesda, MD, USA.
Jonathan KeatsTranslational Genomics Research Institute, Phoenix, AZ, USA.
Craig ThomasChemical Genomics Center, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, Bethesda, MD, USA.
Beverly A MockLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. mockb@mail.nih.gov.ORCID http://orcid.org/0000-0003-2479-4549

Funding

Preclinical Testing of HDAC, mTOR and MYC InhibitorsZIABC011065 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MOCK, BEVERLY · 2009 to 2025
$10.6M
The Genetics of Susceptibility to Mouse Plasma Cell TumorsZIABC010008 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MOCK, BEVERLY · 2009 to 2025
$9.0M
THE GENETICS OF SUSCEPTIBILITY TO MOUSE PLASMA CELL TUMORSZ01BC010008 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MOCK, BEVERLY A. · 1996 to 2008
$1.7M
Intramural NIH HHS Z01 BC010008Multiple Myeloma Research Foundation (Multiple Myeloma Research Foundation, Inc.) Trainee Fellowship GrantU.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) ZIA BC 010008U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) ZIA BC 011065
6 · The paper itself

Abstract

Multiple myeloma, a hematopoietic malignancy of terminally differentiated B cells, is the second most common hematological malignancy after leukemia. While patients have benefited from numerous advances in treatment in recent years resulting in significant increases to average survival time following diagnosis, myeloma remains incurable and relapse is common. To help identify novel therapeutic agents with efficacy against the disease and to search for biomarkers associated with differential response to treatment, a large-scale pharmacological screen was performed with 1,912 small molecule compounds tested at 11 doses for 47 human myeloma cell lines (HMCL). Raw and processed versions of the drug screen dataset are provided, as well as supportive information including drug and cell line metadata and high-level characterization of the most salient features of each. The dataset is publicly available at Zenodo and the workflow code used for data processing and generation of supporting figures and tables are available on GitHub.

Indexed as

Antineoplastic AgentsMultiple MyelomaSmall Molecule LibrariesCell Line, TumorDrug Screening Assays, AntitumorHumansAntineoplastic AgentsSmall Molecule Libraries

Identifiers

PMID40253396
PMCPMC12009346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.